

Roman Fischer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1402436/publications.pdf>

Version: 2024-02-01

32
papers

1,944
citations

331538

21
h-index

477173

29
g-index

32
all docs

32
docs citations

32
times ranked

3072
citing authors

#	ARTICLE	IF	CITATIONS
1	Role of Peripheral Immune Cells for Development and Recovery of Chronic Pain. <i>Frontiers in Immunology</i> , 2021, 12, 641588.	2.2	26
2	The TNFR1 Antagonist Atrosimab Is Therapeutic in Mouse Models of Acute and Chronic Inflammation. <i>Frontiers in Immunology</i> , 2021, 12, 705485.	2.2	19
3	Fundamentally different roles of neuronal TNF receptors in CNS pathology: TNFR1 and IKK β promote microglial responses and tissue injury in demyelination while TNFR2 protects against excitotoxicity in mice. <i>Journal of Neuroinflammation</i> , 2021, 18, 222.	3.1	25
4	Synaptic alterations and immune response are sexually dimorphic in a non-pertussis toxin model of experimental autoimmune encephalomyelitis. <i>Experimental Neurology</i> , 2020, 323, 113061.	2.0	14
5	Inflammation and Oxidative Stress in Multiple Sclerosis: Consequences for Therapy Development. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-19.	1.9	73
6	Selective Targeting of TNF Receptors as a Novel Therapeutic Approach. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 401.	1.8	126
7	Attenuating Neurogenic Sympathetic Hyperreflexia Robustly Improves Antibacterial Immunity After Chronic Spinal Cord Injury. <i>Journal of Neuroscience</i> , 2020, 40, 478-492.	1.7	24
8	TNF-Receptor-1 inhibition reduces liver steatosis, hepatocellular injury and fibrosis in NAFLD mice. <i>Cell Death and Disease</i> , 2020, 11, 212.	2.7	90
9	Development of a Mouse Pain Scale Using Sub-second Behavioral Mapping and Statistical Modeling. <i>Cell Reports</i> , 2019, 28, 1623-1634.e4.	2.9	65
10	Exogenous activation of tumor necrosis factor receptor 2 promotes recovery from sensory and motor disease in a model of multiple sclerosis. <i>Brain, Behavior, and Immunity</i> , 2019, 81, 247-259.	2.0	26
11	Continuous infusion of an agonist of the tumor necrosis factor receptor 2 in the spinal cord improves recovery after traumatic contusive injury. <i>CNS Neuroscience and Therapeutics</i> , 2019, 25, 884-893.	1.9	14
12	Tumor necrosis factor receptor 1 inhibition is therapeutic for neuropathic pain in males but not in females. <i>Pain</i> , 2019, 160, 922-931.	2.0	37
13	Superior Treg-Expanding Properties of a Novel Dual-Acting Cytokine Fusion Protein. <i>Frontiers in Pharmacology</i> , 2019, 10, 1490.	1.6	14
14	TNFR2 promotes Treg-mediated recovery from neuropathic pain across sexes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 17045-17050.	3.3	45
15	Soluble TNF α Signaling within the Spinal Cord Contributes to the Development of Autonomic Dysreflexia and Ensuing Vascular and Immune Dysfunction after Spinal Cord Injury. <i>Journal of Neuroscience</i> , 2018, 38, 4146-4162.	1.7	42
16	The E3 ubiquitin ligases HOIP and cIAP1 are recruited to the TNFR2 signaling complex and mediate TNFR2-induced canonical NF- κ B signaling. <i>Biochemical Pharmacology</i> , 2018, 153, 292-298.	2.0	27
17	Selective Activation of Tumor Necrosis Factor Receptor α Induces Antiinflammatory Responses and Alleviates Experimental Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 722-735.	2.9	34
18	Anti-TNFR1 targeting in humanized mice ameliorates disease in a model of multiple sclerosis. <i>Scientific Reports</i> , 2018, 8, 13628.	1.6	41

#	ARTICLE	IF	CITATIONS
19	Novel strategies to mimic transmembrane tumor necrosis factor-dependent activation of tumor necrosis factor receptor 2. <i>Scientific Reports</i> , 2017, 7, 6607.	1.6	34
20	Essential protective role of tumor necrosis factor receptor 2 in neurodegeneration. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 12304-12309.	3.3	129
21	Interrelation of Oxidative Stress and Inflammation in Neurodegenerative Disease: Role of TNF. <i>Oxidative Medicine and Cellular Longevity</i> , 2015, 2015, 1-18.	1.9	486
22	Targeting sTNF/TNFR1 Signaling as a New Therapeutic Strategy. <i>Antibodies</i> , 2015, 4, 48-70.	1.2	63
23	Antibody-Mediated Inhibition of TNFR1 Attenuates Disease in a Mouse Model of Multiple Sclerosis. <i>PLoS ONE</i> , 2014, 9, e90117.	1.1	55
24	Astrocyte-specific activation of TNFR2 promotes oligodendrocyte maturation by secretion of leukemia inhibitory factor. <i>Glia</i> , 2014, 62, 272-283.	2.5	91
25	Genetic engineering of a TNFR2 agonist to promote immunomodulation and neuroprotection. <i>Journal of Neuroimmunology</i> , 2014, 275, 218.	1.1	0
26	Anti-TNFR1 targeting in humanized mice ameliorates disease in a model of multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2014, 275, 178-179.	1.1	0
27	TNF receptor 2 protects oligodendrocyte progenitor cells against oxidative stress. <i>Biochemical and Biophysical Research Communications</i> , 2013, 440, 336-341.	1.0	49
28	Role of Caspases in Cytokine-Induced Barrier Breakdown in Human Brain Endothelial Cells. <i>Journal of Immunology</i> , 2012, 189, 3130-3139.	0.4	112
29	Characterization of mouse cell line IMA 2.1 as a potential model system to study astrocyte functions. <i>ALTEX: Alternatives To Animal Experimentation</i> , 2012, 29, 261-274.	0.9	18
30	Ligand-induced internalization of TNF receptor 2 mediated by a di-leucine motif is dispensable for activation of the NF- κ B pathway. <i>Cellular Signalling</i> , 2011, 23, 161-170.	1.7	37
31	A TNF Receptor 2 Selective Agonist Rescues Human Neurons from Oxidative Stress-Induced Cell Death. <i>PLoS ONE</i> , 2011, 6, e27621.	1.1	103
32	Neuropathic Pain in Multiple Sclerosis—Current Therapeutic Intervention and Future Treatment Perspectives. , 0, , 53-69.		25